SEARCH

SEARCH BY CITATION

References

  • Basaria S., Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110: 563572.
  • Basaria S., Lieb J 2nd, Tang A., DeWeese T., Carducci M., Eisenberger M., Dobs AS. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol. 2002;56: 779786.
  • Basaria S., Muller DC, Carducci MA, Egan J., Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer. 2006;106: 581588.
  • Basaria S., Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86: 51085117.
  • Braga-Basaria M., Dobs AS, Muller DC, Carducci MA, John M., Egan J., Basaria S.. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24: 39793983.
  • Bubley GJ, Carducci M., Dahut W., Dawson N., Daliani D., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17: 34613467.
  • Chen Z., Maricic M., Nguyen P., Ahmann FR, Bruhn R., Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95: 21362144.
  • Chodak GW. Comparing treatments for localized prostate cancer—persisting uncertainty. JAMA. 1998;280: 10081010.
  • Chodak GW, Keane T., Klotz L.. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002;60: 201208.
  • Cutolo M., Sulli A., Capellino S., Villaggio B., Montagna P., Seriolo B., Straub RH. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13: 635638.
  • D'Amico AV, Denham JW, Crook J., Chen MH, Goldhaber SZ, Lamb DS, Joseph D., Tai KH, Malone S., Ludgate C., Steigler A., Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25: 24202425.
  • Dockery F., Bulpitt CJ, Agarwal S., Donaldson M., Rajkumar C.. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104: 195201.
  • Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365: 14151428.
  • Expert Panel on Detection. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 24862497.
  • Garnick MB, Pratt CM, Campion M., Shipley J.. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol. 2004;22: 4578.
  • Haffner SM, Shaten J., Stern MP, Smith GD, Kuller L.. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;143: 889897.
  • Haffner SM, Valdez RA, Mykkanen L., Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism. 1994;43: 599603.
  • Huggins C., Stevens RE Jr, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43: 209223.
  • Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57: 4366.
  • Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24: 44484456.
  • Laaksonen DE, Niskanen L., Punnonen K., Nyyssönen K., Tuomainen TP, Valkonen VP, Salonen R., Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27: 10361041.
  • Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70: 11041108.
  • Lee H., McGovern K., Finkelstein J., Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104: 16331637.
  • Lu-Yao G., Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171: 22852290.
  • Marin P., Holmang S., Jonsson L., Sjöström L., Kvist H., Holm G., Lindstedt G., Björntorp P.. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992;16: 991997.
  • Messing EM, Manola J., Sarosdy M., Wilding G., Crawford ED, Trump D.. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341: 17811788.
  • Muller M., Grobbee DE, den Tonkelaar I., Lamberts SW, van Der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90: 26182623.
  • Pitteloud N., Hardin M., Dwyer AA, Valassi E., Yialamas M., Elahi D., Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90: 26362641.
  • Saigal CS, Gore JL, Krupski TL, Hanley J., Schonlau M., Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110: 14931500.
  • Satariano WA, Ragland KE, van den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83: 11801188.
  • Shahinian VB, Kuo YF, Freeman JL, Orihuela E., Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103: 16151624.
  • Sharifi N., Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294: 238244.
  • Smith JC, Bennett S., Evans LM, Kynaston HG, Parmar M., Mason MD, Cockcroft J.R., Scanlon MF, Davies JS. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86: 42614267.
  • Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007;14: 247254.
  • Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87: 599603.
  • Smith MR, Lee H., Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91: 13051308.
  • Tsai HK, D'Amico AV, Sadetsky N., Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99: 15161524.